New Edge Advisors, LLC Corcept Therapeutics Inc Transaction History

New Edge Advisors, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$22.21 - $34.48 $12,482 - $19,377	562 New	562 $18,000
Q4 2023 Feb 13, 2024	SELL	$24.82 - $32.88 $2,730 - $3,616	-110 Reduced 8.54%	1,178 $38,000
Q3 2023 Nov 14, 2023	SELL	$21.97 - $33.8 $725 - $1,115	-33 Reduced 2.5%	1,288 $35,000
Q2 2023 Aug 14, 2023	SELL	$21.44 - $25.15 $3,001 - $3,521	-140 Reduced 9.58%	1,321 $29,000
Q1 2023 May 12, 2023	SELL	$19.2 - $24.47 $140,524 - $179,095	-7,319 Reduced 83.36%	1,461 $31,000
Q4 2022 Feb 14, 2023	SELL	$19.95 - $29.96 $700,284 - $1.05 Million	-35,102 Reduced 79.99%	8,780 $178,000
Q3 2022 Nov 14, 2022	BUY	$24.7 - $29.12 $225,881 - $266,302	9,145 Added 26.33%	43,882 $1.13 Million
Q2 2022 Aug 09, 2022	SELL	$17.33 - $25.3 $39,633 - $57,861	-2,287 Reduced 6.18%	34,737 $826,000
Q1 2022 May 13, 2022	BUY	$16.53 - $25.21 $612,006 - $933,375	37,024 New	37,024 $833,000

350

86.1M

1.12M

667K

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $5.92B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on New Edge Advisors, LLC with notifications on news.